000			01979nmc a2200241 4500
005			20260520005820.0
008			260224s xxu
082			_aCD I249 1 0013788
245	0	0	_aEstablishment of a 13CH4 enrichment plant for medical applications at an LNG terminal
270			_a12/09/06 ; 22/07/2003
300			_a9 p.
500			_aDisponible en CD en formato PDF
520			_aTranscripción del abstract original del autor: 12C and 13C are two stable carbon isotopes. Their ratios in the natural environment are 98.9% and 1.1% respectively. Carbon molecules in methane, the primary component of LNG, also contain the isotopes in the same ratio. With enrichment, the unique features of these isotopes can be utilized. It is our intent to utilize 13C, particularly in the medical field. When a 13C-labeled compound is combined with the technology for its detection, an early diagnosis of diseases can be made by monitoring in vivo the metabolism of the compound. One particular application is the 13C-urea breath test, which has come into practical use recently as a means to diagnose Helicobacter pylori infection, one of the causes of gastric ulcers and some other stomach ailments. Tokyo Gas has developed low-temperature distillation technology for the enrichment of 13CH4 from LNG to answer the need for a relatively inexpensive supply of 13C in large cuantities. Presently, we have succeeded in constructing the world’s first commercial-scale 13CH4 enrichment plant, which uses LNG both as its raw material and as the source of cryogenic energy required for 13CH4 distillation.
773			_g
942			_cCONGTP
100	1		_aHori, Kazuhide _922215
100	1		_aMonguchi, Takuo _922216
110	2		_aInternational Gas Union, IGU _913105
111	2		_aWorld Gas Conference (22nd. : 2003 jun 1-5 : Tokyo) _922029
700	1		_aMonguchi, Takuo _922216
710	2		_aInternational Gas Union, IGU _913105
999			_c149612 _d149612